Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: La Jolla Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

La Jolla Diagnostics: Announces "close-out" sale of its inventory of antisera (various reagents containing antibodies that counter immunoglobulins) to focus on other products. A breast cancer diagnostic test using DNA fingerprinting technology and a heart attack predictor are currently in development, as is an ophthalmic and nasal spray product line. The close-out should bring in "significant revenue" in the next three years, the La Jolla, California company predicts...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts